Meta-analysis showing that early response to neoadjuvant chemotherapy predicts better survival among cervical cancer patients
Metrics: PDF 1146 views | HTML 1561 views | ?
Zhilan Chen1,*, Yachen Shi2,*, Shixuan Wang3 and Qiping Lu4
1Department of Obstetrics and Gynecology, Wuhan General Hospital of Guangzhou Military Command, Wuhan, Hubei, China
2School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
3Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
4Department of General Surgery, Wuhan General Hospital of Guangzhou Military Command, Wuhan, Hubei, China
Shixuan Wang, email: email@example.com
Qiping Lu, email: firstname.lastname@example.org
Keywords: cervical cancer, early response, survival, neoadjuvant chemotherapy, meta-analysis
Received: November 11, 2016 Accepted: July 06, 2017 Published: July 21, 2017
This study was designed to identify the prognostic value of early response to neoadjuvant chemotherapy (NACT) for long-term survival of cervical cancer patients. We searched Pubmed and EMBASE for studies published through July 2016 on outcomes of cervical patients that received NACT. Eight studies involving 825 cervical cancer patients were ultimately included in our meta-analysis. We pooled the hazard ratios (HR) according to random-effects models and used funnel plots with Egger’s and Begg’s tests to explore potential publication bias. The HR between early response and 1-year overall survival (OS) was 3.60 (95% CI 1.93–6.72; I2 = 0). Similar results were found in the analysis of 3-year OS (HR 3.34; 95% CI 2.28–4.90; I2 = 0) and 5-year OS (HR 3.44; 95% CI 2.40–4.94; I2 = 0). Sensitivity analysis showed that all of the pooled results were robust, and all logHRs had confidence limits > 0. Our findings indicate that early response is associated with long-term survival, and responders achieved a higher survival rate than non-responders.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.